GlaxoSmithKline R&D chief to retire

GlaxoSmithKline R&D chief Tadataka “Tachi” Yamada will retire from his post on June 1 to take up the role of global health executive director for the Bill & Melinda Gates Foundation. Moncef Slaoui, GSK’s current head of worldwide business development and external research alliances, will replace Yamada. In a statement issued today, Yamada, who has overseen R&D at GSK’s North American headquarters since 2001, said, “Our R&D organization is in excellent shape and I am confident that under Moncef's leadership, GSK will continue to deliver many innovative medicines of significant value to patients.” Slaoui has helped GSK restructure its R&D operations “to enhance drug discovery and accelerate product development” on products including the recently approved vaccine Rotarix for infantile gastroenteritis, and Cervarix for cervical cancer, the drug maker said in a statement.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.